Inhibikase Therapeutics (IKT) Notes Payables (2020 - 2021)
Inhibikase Therapeutics (IKT) posted quarterly Notes Payables of $248911.0 for Q4 2021, up 485.2% year-over-year from $42534.0 in Q4 2020, and little changed quarter-over-quarter from $248911.0 in Q3 2021.
Inhibikase Therapeutics (IKT) Notes Payables (2020 - 2021) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Notes Payables for 2 consecutive years, with $248911.0 the latest figure, recorded in Q4 2021.
- In Q4 2021, Notes Payables rose 485.2% year-over-year to $248911.0; the TTM figure through Dec 2021 stood at $248911.0 (up 485.2% YoY), while the FY2021 annual figure was $248911.0, up 485.2% from the prior year.
- Notes Payables steadied at $248911.0 in Q4 2021 per IKT's latest filing, from $248911.0 in the prior quarter.
- Across five years, Notes Payables topped out at $994789.0 in Q1 2021 and bottomed at $42534.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 248,911.00 |
| Sep 30, 2021 | 248,911.00 |
| Mar 31, 2021 | 994,789.00 |
| Dec 31, 2020 | 42,534.00 |